Modern approaches in treatment of diabetes mellitus type 2: glucagon-like peptide-1 receptor agonist and basal insulin combination
AbstractDiabetes mellitus type 2 is extremely widespread chronic disease characterized by progressive course and led to patients’ disability. Obesity, associated insulin resistance and the depletion of pancreatic β-cells functional activity play an important role in pathogenesis of diabetes mellitus type 2. In recent years there was presented a new group of preparations with a good profile of efficiency and safety, which action is based on the incretin effect. The glucagon-like peptide-1 (GLP-1) receptor agonist therapy leads to weight reduction and improvement of a carbohydrate metabolism indicators without significant increase of hypoglycemic states development risk. Combination «exenatide + prolonged insulin» is the high-perspective treatment modality which has some advantages for difficult category of patients with diabetes mellitus type 2 (the obesity patients demanding purpose of an insulin therapy for achievement of compensation of a carbohydrate exchange).
Keywords:diabetes mellitus type 2, incretin, exenatide, prolonged insulin, combine antihyperglycemic therapy, new combinations of blood glucose lowering drugs
Endocrinology: News, Opinions, Training. 2014; (4): 29–36.